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TO THE EDITOR: We wish to call for the removal of scheduling and legislative barriers in Australia that 
prevent easy access to naloxone for administration by peers to people suffering from a heroin overdose.  
Use of illicit opioids, typically heroin, remains the major cause of illicit drug-related mortality in this 
country, with at least one accidental opioid overdose currently occurring each day.1, Although population 
levels have not reached those seen during the peak in the late 1990s, geographically localised and 
transient increases in overdoses are evident2  
Mortality from heroin overdose typically occurs some time after use. In many cases, other people are 
present, and there is considerable scope for intervention to prevent death.3 Yet, in more than 70% of cases 
of fatal overdose, there is no intervention, and, where action is taken, calling an ambulance is seldom the 
first strategy, resulting in even greater risk of mortality.3 
Opioid substitution treatment (with methadone or buprenorphine) is the mainstay of overdose 
prevention in Australia. Other interventions implemented here include outreach services and education for 
injecting drug users about the risks of overdose and how to respond to it.3 
In 2000, Lenton and Hargreaves summarised the evidence for distributing the opioid antagonist 
naloxone for administration by peers to prevent deaths from heroin overdose. They concluded that an 
Australian research trial was needed.4 When, in 2001, the Australian heroin market was disrupted and 
heroin use and overdoses declined, the trial did not proceed.  
Since then, emerging international evidence has demonstrated that injecting drug-using peers, family 
members and outreach workers can successfully administer naloxone to reverse heroin overdose — with 
few, if any, adverse effects.5 By December 2008 in the United States, 52 programs distributing naloxone 
for administration by peers were operating in 17 states, with over 1000 documented overdose reversals 
resulting from these programs.5 Most concerns about the intervention — such as the possibility of unsafe 
naloxone administration, reintoxication or more risky drug use — appear to have been unfounded, and 
naloxone administration by trained peers has been shown to be a remarkably safe intervention.5 
In our view, the international evidence clearly indicates that increased naloxone availability will prevent 
many cases of fatal overdose, that conducting a trial in Australia is now unnecessary, and that naloxone 
should be made available without delay to be administered by peers in cases of opioid overdose. Careful 
monitoring and evaluation should be a part of this process.  
We call on all Australian states and territories to immediately enact Good Samaritan legislation to 
legally protect lay people using naloxone in emergency situations. Naloxone should be reclassified from a 
Schedule 4 (S4) drug (available only on prescription) to S3 or S2 to make it available over the counter. As 
naloxone is no longer under patent,5 there may be little financial incentive for a drug company to pursue 
rescheduling. However, it could be rescheduled in Australia under provisions that allow state health 
authorities, professional associations or the National Drugs and Poisons Schedule Committee to initiate 
the process.  
Heroin overdose deaths are preventable. We need to take action now to enable this peer-led intervention 
to reduce this serious outcome. 
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